NGM282, a novel variant of FGF19, significantly reduces hepatic steatosis and key biomarkers of NASH: results of a Phase 2, multicenter, randomized, double-blinded, placebo controlled trial in biopsy-confirmed NASH patients
Authors:
- S.A. HarrisonSHS.A. Harrison
- M.F. AbdelmalekMAM.F. Abdelmalek
- J.F. TrotterJTJ.F. Trotter
- A.H. ParedesAPA.H. Paredes
- H.L. ArnoldHAH.L. Arnold
- M. KugelmasMKM. Kugelmas
- M.R. BashirMBM.R. Bashir
- L. LingLLL. Ling
- S.J. RossiSRS.J. Rossi
- A.M. DePaoliADA.M. DePaoli
- M.E. RinellaMRM.E. Rinella
- R.S. LoombaRLR.S. Loomba
- 1 January 2017
- journal article
- Published by Elsevier in Journal of Hepatology
- Vol. 66 (1) , S92-S93